Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Showing results for "early lung health"

Research

Vitamin D and Sunlight

In a sunny country such as Australia, it’s important to identify how to achieve the right amount of sun exposure for good health. We need to be able to harness the benefits of vitamin D and sunlight while remaining protected from the proven dangers of too much UV radiation.

Current Studies

The Western Australian Epithelial Research Program (WAERP) biobank is undertaking a number of research projects intended to improve the understanding and preclinical assessment of therapeutics for respiratory conditions.

News & Events

Funding boost for groundbreaking child health research

Researchers from The Kids Research Institute Australia will share in almost $4 million in grants to continue groundbreaking research to tackle childhood cancer, asthma, respiratory viral infections and more.

News & Events

Sun safe: balancing the risks and benefits

The D-Light program, set up in 2014, aims to shed light on the amount of sun exposure that will promote good health in children and adolescents.

News & Events

New test proves effective in more cancers

Avantogen Limited (ACU:ASX) today announced that cancer researchers at Perth's The Kids for Child Health Research (TICHR) and Avantogen Limited

Research

Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea

Vaccination trials in high endemicity areas are needed to provide evidence and guidance on idea strategies to protect children in these areas against infections

Research

A systems biology approach to determining the risk for development of otitis media

Peter Ruth Elke Richmond Thornton Seppanen MBBS MRCP(UK) FRACP PhD BSc PhD Head, Vaccine Trials Group Co-head, Bacterial Respiratory Infectious

Research

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.

Research

Clinical predictors of hypoxic pneumonia in children from the Eastern Highlands Province, Papua New Guinea: secondary analysis of two prospective observational studies

Pneumonia is the leading cause of death in young children globally and is prevalent in the Papua New Guinea highlands. We investigated clinical predictors of hypoxic pneumonia to inform local treatment guidelines in this resource-limited setting.